ADC, in association with PSA, represents a potential biomarker imaging for evaluating treatment efficacy in PCa both during and shortly after RT.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Prostate specific antigen (PSA) remains the most used test to assess the response after therapies including the radiation therapy (RT).
📊
Temel Bulgular & Veri:Apparent diffusion coefficient (ADC) derived from the conventional diffusionweighted imaging (DWI), as a part of noncontrast or biparametric MRI (bpMRI) (T2-weighted and DWI), offers diagnostic accuracy and cancer detection rate equivalent to that of multiparametric MRI.
💡
Sonuç & Katkı:ADC, in association with PSA, represents a potential biomarker imaging for evaluating treatment efficacy in PCa both during and shortly after RT.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Özet
Prostate specific antigen (PSA) remains the most used test to assess the response after therapies including the radiation therapy (RT). Apparent diffusion coefficient (ADC) derived from the conventional diffusionweighted imaging (DWI), as a part of noncontrast or biparametric MRI (bpMRI) (T2-weighted and DWI), offers diagnostic accuracy and cancer detection rate equivalent to that of multiparametric MRI. Cellular changes induced by RT can be quali-qualitatively demonstrated as early as 3months after RT as an increase in the signal intensity of the tumor on the ADC map. ADC, in association with PSA, represents a potential biomarker imaging for evaluating treatment efficacy in PCa both during and shortly after RT.
🔖
Bu Makaleye Atıf Yap
SCİALPİ, M., MARTORANA, E., SCIALPI, P., ANDREA, A. D., MANCIOLI, F., MIGNOGNA, M., BLASI, A. D., TRIPPA, F. (2021). MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. Turkish Journal of Urology, Cilt: 47 - Sayı: 6, 448–451. https://ajindex.com/articles/404220
Siegel RL, Miller KD, Fuchs HE, Jemad A. Cancer statistics 2021. Cancer J Clin. 2021
71(1):7-33. [CrossRef] 2. Roach M 3rd. Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: “love the one you’re with” and “do the right thing”. Int J Radiat Oncol Biol Phys. 2003
57(4):907-909. [CrossRef] 3. Kuhl CK, Bruhn R, Kra¨mer N, Nebelung S, Heidenreich A, Schrading S. Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen. Radiology. 2017
[CrossRef] 4. Scialpi M, Prosperi E, D’Andrea A, et al. Biparametric versus multiparametric MRI with non-endorectal coil at 3T in the detection and localization of prostate cancer. Anticancer Res. 2017
37(3):1263-1271. [CrossRef] 5. Scialpi M, D’Andrea A, Martorana E, et al. Biparametric MRI of the prostate. Turkish J Urol. 2017
43(4):401-409. [Cross- Ref] 6. Jung JW, Kang HR, Kim MH, et al. Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology. 2012
[Database] [CrossRef] 7. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015
[CrossRef] 8. Sener RN. Diffusion MRI: Apparent diffusion coefficient (ADC) values in the normal brain and a classification of brain disorders based on ADC values. Comput Med Imaging Graph. 2001
25(4):299-326. [CrossRef] 9. Kim TH, Kim CK, Park BK, et al. Relationship between Gleason score and apparent diffusion coefficients of diffusion weighted magnetic resonance imaging in prostate cancer patients. Can Urol Assoc J. 2016
Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging biochemical recurrence after prostatectomy: Where are we headed? AJR Am J Roentgenol. 2020
214(6):1248-1258. [Cross- Ref] 11. Verma S, Rajesh A, Morales H, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol. 2011 Feb
196(2):374-81. [CrossRef] 12. Wu X, Reinikainen P, Vanhanen A, et al. Correlation between apparent diffusion coefficient value on diffusion-weighted MR imaging and Gleason score in prostate cancer. Diagn Interv Imaging. 2017
98(1):63-71. [CrossRef] 13. Scialpi M, Martorana E, Scialpi P, et al. Round table: Arguments in supporting abbreviated or biparametric MRI of the prostate protocol. Abdom Radiol. 2020